The impact of accelerated 40 Hz transcranial alternating current stimulation on sleep in patients with major depressive disorder: A secondary analysis of a randomized controlled trial.

J Affect DisordMay 29, 2026 (epub)
Clinical ResearchPsychiatry

Ziyao Zhang, Zhiwang Liu, Yanping Ji et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of a randomized controlled trial evaluated the effects of accelerated 40 Hz transcranial alternating current stimulation (tACS) on sleep in patients with major depressive disorder (MDD). The study involved 70 participants, with the active tACS group showing a significant reduction in Pittsburgh Sleep Quality Index (PSQI) total score compared to the sham group, indicating improved sleep quality.

Key findings

  • Active tACS group had a significant reduction in PSQI total score from baseline to Week 2.
  • Improvements were noted in subjective sleep quality, sleep efficiency, and sleep disturbance.
  • Greater reductions in insomnia factor scores were observed in the active group compared to sham.

Why it matters

Sleep disturbances are common in major depressive disorder and can worsen clinical outcomes. Effective interventions targeting sleep may enhance overall treatment efficacy and reduce relapse risk in this population.

Source

PubMed · PMID 42217647

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.